title: Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study.
abstract: BACKGROUND
  Taxanes have been widely used against advanced non-small cell lung cancer (NSCLC), alone and in combination with platinum agents. In order to develop a tolerable palliative regimen, we combined carboplatin with low dose docetaxel.
  
  
  METHODS
  Chemotherapy-naive patients, with Stage IIIB or IV NSCLC and an ECOG performance status < or = 2, were enrolled. Treatment consisted of docetaxel 60 mg/m2 and carboplatin AUC 6 every 21 days. Therapy continued for 1 year or 6 months beyond best response, whichever was greater.
  
  
  RESULTS
  Twenty-five patients were enrolled. Most patients (80%) had Stage IV disease. The partial response rate was 16%. Response duration ranged from 6 to 115 weeks. Median survival was 55 weeks. Toxicity was generally limited to grade 3 or 4 neutropenia. There was 1 septic death.
  
  
  CONCLUSIONS
  Survival compared favorably to other similar trials employing higher doses of docetaxel. Additionally, a hematologic toxicity advantage was seen compared to regimens containing higher doses of docetaxel.
authors.affiliation: University of Tennessee Cancer Institute, 1331 Union Avenue-Suite 800, Memphis, TN 38104, USA. mjahanze@utmem.edu
authors.forename: Mohammad
authors.initials: M
authors.lastname: Jahanzeb
authors.forename: Greg
authors.initials: G
authors.lastname: Sarna
authors.forename: Robert
authors.initials: R
authors.lastname: Hirsch
authors.forename: Peter
authors.initials: P
authors.lastname: Radice
authors.forename: Alan
authors.initials: A
authors.lastname: Koletsky
authors.forename: Manuel
authors.initials: M
authors.lastname: Martinez
authors.forename: Elena
authors.initials: E
authors.lastname: Kruglyak
authors.forename: Edward
authors.initials: E
authors.lastname: Wolin
authors.forename: Elber
authors.initials: E
authors.lastname: Camacho
authors.forename: Lori
authors.initials: L
authors.lastname: Kronish
authors.forename: Susannah
authors.initials: S
authors.lastname: Motl
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin